Dr. Shalini Mohan joined Genentech in 2015 in Global Safety Science in which she was responsible for the pharmacovigilance for multiple molecules and supported late stage clinical trials, one of which led to the filing and approval of tocilizumab for giant cell arteritis. Shalini currently leads a team focused on advancing health equity through inclusive research and supporting access to trials and healthcare for underserved populations in the US. She conducted the largest randomized placebo-controlled trial for COVID-19 pneumonia and was successful in enrolling 85% historically underrepresented patients. This trial has become foundational for Genentech’s mission to be a leader in health equity research. Prior to Genentech Shalini was a Clinical Research Fellow in Oncology and Dermatology and a Postdoctoral Fellow at Stanford University. She has authored more than 25 peer-review publications and received multiple awards including the 2023 Genentech Professional BusinessWomen of California (PBWC) Industry Leader Award.
